Aprea Therapeutics, Inc. (NASDAQ:APRE – Get Rating) – Wedbush lowered their FY2022 earnings estimates for Aprea Therapeutics in a report issued on Thursday, November 10th. Wedbush analyst R. Driscoll now forecasts that the company will earn ($0.36) per share for the year, down from their previous estimate of $1.19. The consensus estimate for Aprea Therapeutics’ current full-year earnings is ($0.28) per share. Wedbush also issued estimates for Aprea Therapeutics’ Q4 2022 earnings at ($0.12) EPS, FY2023 earnings at ($0.42) EPS, FY2024 earnings at ($0.38) EPS, FY2025 earnings at ($0.39) EPS and FY2026 earnings at $0.06 EPS.
Separately, HC Wainwright reaffirmed a “buy” rating and issued a $3.00 target price on shares of Aprea Therapeutics in a report on Monday, October 10th.
Aprea Therapeutics Stock Performance
Aprea Therapeutics (NASDAQ:APRE – Get Rating) last issued its quarterly earnings results on Thursday, August 11th. The company reported ($0.99) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.61).
Institutional Trading of Aprea Therapeutics
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Jane Street Group LLC acquired a new stake in Aprea Therapeutics during the second quarter worth approximately $54,000. Renaissance Technologies LLC raised its holdings in Aprea Therapeutics by 4.7% during the second quarter. Renaissance Technologies LLC now owns 311,754 shares of the company’s stock worth $234,000 after purchasing an additional 13,854 shares in the last quarter. Finally, Gyon Technologies Capital Management LP acquired a new stake in Aprea Therapeutics during the first quarter worth approximately $38,000. Institutional investors and hedge funds own 18.95% of the company’s stock.
Aprea Therapeutics Company Profile
Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors.
- Get a free copy of the StockNews.com research report on Aprea Therapeutics (APRE)
- Alphabet Stock Offers a Rare Buying Opportunity
- Solar Battery Maker Enphase Clears Buy Point: Can Rally Hold?
- Walt Disney Stock is Set to Reset Expectations
- S&P 500 Component DexCom Set For Further Price, Earnings Growth
- MarketBeat: Week in Review 11/7 – 11/11
Receive News & Ratings for Aprea Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aprea Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.